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Abstract
Background: Hepatic ischemia-reperfusion injury (I/Ri) is a serious complication occurring during liver surgery that 
may lead to liver failure. Hepatic I/Ri induces formation of reactive oxygen species, hepatocyte apoptosis, and release of 
pro-inflammatory cytokines, which together causes liver damage and organ dysfunction. A potential strategy to 
alleviate hepatic I/Ri is to exploit the potent anti-inflammatory and cytoprotective effects of carbon monoxide (CO) by 
application of so-called CO-releasing molecules (CORMs). Here, we assessed whether CO released from CORM-2 
protects against hepatic I/Ri in a rat model.
Methods: Forty male Wistar rats were randomly assigned into four groups (n = 10). Sham group underwent a sham 
operation and received saline. I/R group underwent hepatic I/R procedure by partial clamping of portal structures to 
the left and median lobes with a microvascular clip for 60 minutes, yielding ~70% hepatic ischemia and subsequently 
received saline. CORM-2 group underwent the same procedure and received 8 mg/kg of CORM-2 at time of 
reperfusion. iCORM-2 group underwent the same procedure and received iCORM-2 (8 mg/kg), which does not release 
CO. Therapeutic effects of CORM-2 on hepatic I/Ri was assessed by measuring serum damage markers AST and ALT, 
liver histology score, TUNEL-scoring of apoptotic cells, NFkB-activity in nuclear liver extracts, serum levels of pro-
inflammatory cytokines TNF-α and IL-6, and hepatic neutrophil infiltration.
Results: A single systemic infusion with CORM-2 protected the liver from I/Ri as evidenced by a reduction in serum 
AST/ALT levels and an improved liver histology score. Treatment with CORM-2 also up-regulated expression of the anti-
apoptotic protein Bcl-2, down-regulated caspase-3 activation, and significantly reduced the levels of apoptosis after I/
Ri. Furthermore, treatment with CORM-2 significantly inhibited the activity of the pro-inflammatory transcription factor 
NF-κB as measured in nuclear extracts of liver homogenates. Moreover, CORM-2 treatment resulted in reduced serum 
levels of pro-inflammatory cytokines TNF-α and IL-6 and down-regulation of the adhesion molecule ICAM-1 in the 
endothelial cells of liver. In line with these findings, CORM-2 treatment reduced the accumulation of neutrophils in the 
liver upon I/Ri. Similar treatment with an inactive variant of CORM-2 (iCORM-2) did not have any beneficial effect on the 
extent of liver I/Ri.
Conclusions: CORM-2 treatment at the time of reperfusion had several distinct beneficial effects on severity of hepatic 
I/Ri that may be of therapeutic value for the prevention of tissue damage as a result of I/Ri during hepatic surgery.
Background
Hepatic ischemia-reperfusion injury (I/Ri) is a serious
and common adverse event during hepatic surgery that
may ultimately lead to liver failure, systemic inflamma-
tory response syndrome (SIRS) and even multiple organ
failure syndrome (MOF) [1-4]. Central to hepatic I/Ri is
the generation of reaction oxygen species (ROS) by acti-
vated Kupffer cells or neutrophils upon the reintroduc-
t i o n  o f  m o l e c u l a r  o x y g e n  t o  i s c h e m i c  t i s s u e s .  T h i s
pathogenic event triggers a series of deleterious effects
that include oxidative modification of lipids and proteins,
induction of apoptosis in hepatocytes, release of pro-
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inflammatory cytokines, increased expression of adhe-
sion molecules, and infiltration of leukocytes, which
together leads to massive tissue destruction [5,6].
To ameliorate the severity of liver I/Ri, several thera-
peutic strategies are currently being pursued, including
the inhibition of apoptosis by decreasing cellular metabo-
lism using the gas hydrogen sulphide (H2S). Application
of H2S has shown promising activity in various pre-clini-
cal I/Ri and transplantation models, including kidney and
liver [7,8]. A second interesting strategy is to inhibit mito-
chondrial calcium overload, e.g. with 2-ABP [9], and thus
block the execution of mitochondrial apoptotic signaling
[10]. A third particularly appealing strategy is the use of
anti-oxidants that directly counteract the deleterious
effects of ROS. In this respect, dietary anti-oxidative sup-
plements such as rutin and L-arginine have shown bene-
ficial effects on severity of hepatic I/Ri [11]. Moreover,
carbon monoxide (CO) has raised particular therapeutic
interest because of its potent anti-oxidant and anti-
inflammatory activity.
CO is best known as an odorless and toxic gas which
upon inhalation binds with high affinity to heme, thereby
forming carboxyhemoglobin and severely impairing the
respiratory system. However, CO is also produced by the
protein heme oxygenase (HO) and as such functions as a
potent endogenous antioxidant that counteracts toxic
effects of ROS. HO-1 degrades heme into biliverdin, free
iron, and CO [12] and is one of the most prominent lines
of cellular defense against damage induced by I/Ri.
Indeed, during oxidative stress the expression of the
inducible form of HO, (HO-1) is strongly up-regulated in
the liver [13].
Therapeutic up-regulation of CO tissue levels can be
achieved via exogenous application of CO, for instance by
direct inhalation of CO gas. In ex vivo isolated liver perfu-
sion and liver transplantation models exogenously added
CO yields potent cytoprotective effects [14-16]. More-
over, CO has anti-inflammatory activity e.g. by inhibiting
the inflammatory response of donor Kupffer cells upon
transplantation [17], activation of anti-inflammatory
mitogen-activated protein kinase signaling [18], and up-
regulation of the anti-inflammatory cytokine IL-10 [19].
Furthermore, CO inhibits the acquisition of a pro-adhe-
sive phenotype of vascular endothelial cells [20].
Most studies on the role of CO in the amelioration of
inflammatory responses have been performed by admin-
istration of gaseous CO [21]. However, the applicability of
gaseous CO is limited by its toxic effect on cellular respi-
ration. Therefore, therapeutic use of CO as a cytoprotec-
tive agent clearly requires a pharmaceutical formulation
that allows for the selective delivery and/or local release
of CO from a non-toxic pro-drug. In this respect, transi-
tional metal carbonyl-based compounds are of particular
interest because of their capability for controlled release
of CO in biological systems [22]. These so-called CO-
releasing molecules (CORMs) have been therapeutically
tested in a variety of experimental inflammatory models
with promising anti-inflammatory responses [12,23,24].
Indeed, treatment of septic mice with tricarbonyldichlo-
roruthenium (II) dimer (CORM-2) strongly attenuated
liver inflammation, as evidenced by a decrease in serum
liver damage markers and a reduced influx of inflamma-
tory cells[25]. In addition, CORM-2 was recently
reported to improve outcome of ischemia reperfusion
injury to the small bowel [26]. Importantly, CORM treat-
ment is associated with low or minimal formation of car-
boxyhemoglobin and is therefore considered a safer
alternative to CO gas inhalation [22].
Based on the above, we hypothesized that CORM-2
may ameliorate damage occurring during hepatic I/Ri.
Here, we investigated this hypothesis in a rat model of
experimentally induced hepatic I/Ri.
Methods
Rats and experimental procedure
All animal experiments were performed in accordance
with the experimental protocol approved by the Commit-
tee for Research and Animal E thics of Harbin Medical
University. For the experiments, healthy male Wistar rats
(n = 40; body weight, 230-250 g) were purchased from the
Central Animal Facility of the First Clinical Hospital of
Harbin Medical University (Harbin, China). Rats were
housed in cages under standard animal care conditions
and fed with rat chow ad libitum. All surgical procedures
were performed under general anesthesia using sodium
pentobarbital (50 mg/kg i.p.). Normothermic partial
hepatic ischemia was induced by performing a midline
laparotomy, exposing the liver hilum and subsequent
clamping of portal structures to the left and median lobes
with a microvascular clip, yielding ~70% hepatic ischemia
[27]. The abdomen was covered during the ischemic
period. After 60 min of partial hepatic ischemia, the clip
was removed to initiate hepatic reperfusion and the
abdominal cavity was closed with a 4-0 silk suture. Tem-
perature was maintained at 37°C by a warming pad.
Sham-operated rats underwent the same procedure with-
out clamping the pedicle of the liver lobes.
Rats were randomly assigned into four groups with a
sample size of 10. Sham group underwent a sham opera-
tion and received saline. I/R group underwent the hepatic
I/R procedure and received saline. CORM-2 group
underwent the same procedure and received 8 mg/kg of
CORM-2 (Sigma-Aldrich, St. Louis, MO). iCORM-2
group underwent the same procedure and received
iCORM-2 (8 mg/kg), which does not release CO. All
treatments were administered prior to reperfusion. Rats
were sacrificed by exsanguination at 6 hours post reper-
fusion upon which serum and liver samples were col-Wei et al. BMC Gastroenterology 2010, 10:42
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lected according to standard procedures. Rats in all
experimental conditions survived the 6 hour reperfusion
period.
Serum transaminase determination
At the end of reperfusion, 5 ml of blood was collected
from the caval vein in heparinized tubes. Samples were
centrifuges at 800 g for 10 minutes at room temperature.
Plasma was then used to evaluate the extent of hepatic
injury by measuring serum levels of ALT and AST using
an Automated Chemical Analyzer (7600; Hitachi, Tokyo,
Japan). Values were expressed as units per liter (U/L).
Liver histopathology score
Formalin-fixed liver samples were embedded in paraffin,
sectioned into 5-μm thickness and stained with hematox-
ylin-eosin and microscopically inspected to assess
inflammation and tissue damage. Histological examina-
tion of hepatic tissue damage was performed by two liver
pathologists in a blinded fashion. Ten separated micro-
scopic fields were scored on a scale from 0 to 3 as
described before [28]. The severity of tissue damage was
defined as: grade 0, minimal or no evidence of injury;
grade 1, mild injury consisting of cytoplasmic vacuolation
to focal nuclear pyknosis; grade 2, moderate to severe
injury with extensive nuclear pyknosis, cytoplasmic
hypereosinophilia, and loss of intercellular borders; grade
3, severe necrosis with disintegration of hepatic cords,
hemorrhage, and neutrophil infiltration.
Detection of apoptotic cells by terminal 
deoxyribonucleotide transferase (TdT)-mediated dUTP 
nick-end labeling (TUNEL) staining
TUNEL staining (Roche, Shanghai, China) was applied to
paraffin-embedded 5-μm liver sections to detect DNA
fragmentation as a measure for the number of apoptotic
cells. Counterstaining was performed with 4',6-diami-
dine-2'-phenylindole dihydrochloride (DAPI) dye. Briefly,
deparaffinized livers sections were incubated in permea-
bilization solution (0.1% TritonX-100 in 0.1% sodium cit-
rate) for 2 min on ice, incubated with TUNEL reaction
mixture for 60 min at 37°C in the dark and incubated for
4 min with DAPI dye in the dark. The numbers of apop-
totic cells and total hepatic cells were counted in ten sep-
arated microscopic fields under 400× magnification.
Numbers were then averaged and used to calculate the
apoptosis index (AI) according to the previously reported
formula: AI = (apoptotic cells/total hepatic cells) × 100%
[29].
Myeloperoxidase activity assay
Myeloperoxidase (MPO), an enzyme found predomi-
nantly in azurophilic granules of polymorphonuclear leu-
kocytes, was measured as an index of neutrophil
infiltration in the ischemic liver Briefly, liver tissue was
homogenized, centrifuged at 12.000 g for 15 minutes at
4°C, after which MPO activity was measured using a
commercial kit (NJJC Bio Inc., Nanjing, China) according
to manufacturer's instructions. Absorbance was mea-
sured at 460 nm with a spectrophotometer. MPO activity
was expressed as units per gram protein (U/g).
Cytokine Analysis
Serum samples were obtained from rats 6 h after the I/R
procedure, at the time-point of termination, and stored at
-20°C until further analysis. Serum samples were ana-
lyzed for TNF-α and IL-6 levels using commercially avail-
able enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems, Minneapolis, MN) according to manufac-
turer's instructions. Cytokine levels were expressed as
picogram per ml (pg/ml).
Western blot analysis
Liver whole cell homogenates and nuclear extracts were
obtained by lysis of hepatic tissue with the Nuclear
Extract Kit (Active Motif, Carlsbad, CA) according to
manufacturer instructions. Protein aliquots (50 μg) were
subsequently separated by SDS-PAGE on 5% or 10%
acrylamide gels and proteins were electrotransferred to
PVDF membrane. Protein levels were visualized by incu-
bation with the following antibodies: bcl-2, caspase-3,
ICAM-1, HO-1, NF-κB p65, β-actin, and Histone H1 (all
from Santa Cruz Biotechnology, Inc. Santa Cruz, CA).
Specific binding of antibodies was visualised using appro-
priate horseradish peroxidase-linked secondary antibody
followed by detection of chemoluminescence using an
enhanced chemoluminescence detection kit (Roche)
according to manufacturer's instructions. Blots were
stained with anti-β-actin or Histone H1 antibody to ver-
ify equal protein loading.
Liver nuclear factor-kappa B (NF-κB) activation
Activation of the transcription factor NF-kB was mea-
sured using a commercially available ELISA kit (Trans-
AM™ NF-kB p65 Transcription Factor Assay Kit, Active
Motif, Carlsbad, CA) according to manufacturer's
instructions. Nuclear protein extract was obtained using
Nuclear Extract Kit (Active Motif) according to manufac-
turer's instruction. Subsequently, 15 μg nuclear protein
extract was used to assay for NF-kB activation. Values
were represented as OD450 nm.
Statistical analysis
All values are expressed as the mean ± standard deviation
(SD). Data were analyzed by one-way ANOVA followed
by the Tukey-Kramer post test. For the semi-quantitative
histopathological scores, statistical analysis was per-
formed using the Kruskal-Wallis test followed by the
Dunn's post test. P < 0.05 was considered to indicate sta-
tistical significance.Wei et al. BMC Gastroenterology 2010, 10:42
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Results
CORM-2 attenuates hepatic ischemia reperfusion injury (I/
Ri)
Endogenous CO, produced in response to stress by HO-1,
is an important cellular tool to prevent cytotoxic and pro-
inflammatory effects of ROS. Moreover, in various exper-
imental animal models release of CO by carbon monox-
ide releasing molecules (CORM) has shown promising
cytoprotective and anti-inflammatory activity [12,23,24].
Therefore, we hypothesized that the local release of CO
using CORM-2 might be used for the prevention or
reduction of ROS-mediated hepatic ischemia reperfusion
injury (I/Ri). To test this hypothesis we treated rats sub-
jected to I/R with CORM-2 at the time-point of reperfu-
sion. In untreated I/R rats, the plasma levels of serum
liver damage markers ALT and AST were significantly
increased compared to sham-operated rats (Fig 1A and
1B, respectively; p < 0.001), indicative of significant liver
hepatocyte injury and alterations in hepatic function by I/
Ri. However, a single systemic administration of CORM-
2 at the time-point of reperfusion significantly attenuated
hepatic I/Ri as evidenced by a significant reduction in
ALT and AST levels 6 hours post-reperfusion (Fig. 1A, p
< 0.05 and B, p < 0.05). Semi-quantitative scoring of his-
topathological data confirmed that treatment with
CORM-2 resulted in a significant reduction in liver injury
score of I/Ri rats compared to untreated I/R rats (Fig. 1C,
p < 0.05). Of note, although injury score was markedly
improved by CORM-2 treatment, it was still elevated
compared to sham-operated rats. Importantly, treatment
with an inactive form of CORM-2 (iCORM-2), incapable
of releasing CO, did not reduce liver I/Ri, indicating that
release of CO is important for therapeutic activity (Fig.
1C). Taken together, these data clearly demonstrate that
CO released by CORM-2 can ameliorate the negative
effects of hepatic I/Ri.
CORM-2 treatment inhibits apoptosis in hepatic I/Ri by up-
regulation of Bcl-2
An important consequence of hepatic I/Ri is the loss of
hepatocytes due to induction of apoptosis. Earlier studies
have shown that inhalation of gaseous CO can attenuate
apoptotic cell death in I/Ri models of the heart [30], lung,
kidney [31], and small intestine[32]. Based on these well-
established cytoprotective effects of CO, we assessed
whether CORM-2 treatment reduced the extent of hepa-
tocyte apoptosis in our rat hepatic I/Ri model using
TUNEL staining. In non-ischemic livers of sham-oper-
ated rats only very few apoptotic cells were observed (Fig.
2A), whereas rats subjected to hepatic I/Ri had a dramati-
cally increased number of apoptotic hepatocytes (Fig. 2B,
p < 0.001). Importantly, treatment with CORM-2 mark-
edly reduced the number of apoptotic hepatocytes (Fig.
2C, p < 0.05). In contrast, treatment of rats with iCORM-
2 had no significant protective effect, with comparable
numbers of TUNEL-stained hepatocytes in the non-
treated I/R group and iCORM-2 group (Fig. 2D). Histo-
logical data were confirmed by counting apoptotic hepa-
tocytes to obtain an apoptotic index. I/Ri significantly
increased the apoptotic index compared to sham-oper-
ated rats (p < 0.001). Treatment with CORM-2 signifi-
cantly reduced the apoptosis index compared to rats
subjected to I/Ri (Fig. 2E, p < 0.05). Subsequent Western
blot analysis of homogenized liver tissue confirmed that
apoptosis was indeed inhibited by CORM-2, as evidenced
by a reduction in the level of activation of effector cas-
pase-3 (Fig. 3A and 3B, p < 0.05). Cleaved caspase-3 was
strongly present in the I/Ri group and iCORM-2 treated
group, whereas caspase-3 cleavage was markedly inhib-
ited in CORM-2 treated rats.
The anti-apoptotic effect of CO has among others been
attributed to up-regulation of anti-apoptotic members
and down-regulation of pro-apoptotic members of the
Bcl-2 family [31-33]. Indeed, we detected a strong up-reg-
ulation of the prototype anti-apoptotic protein Bcl-2 in
CORM-2 treated rats when compared to either sham-
operated rats (Fig. 3A, p < 0.001) or I/Ri rats (Fig. 3C, p <
0.05). Expression of Bcl-2 in I/Ri-rats was also increased
in comparison to sham-operated rats, indicative of the
initiation of the tissue homeostatic response. Together,
these results indicate that CORM-2 exerts a protective
Figure 1 CORM-2 attenuates hepatic ischemia reperfusion injury 
(I/Ri). Serum levels of A ALT and B AST of rats subjected to 60 min. of 
ischemia followed by 6 h of reperfusion. C Liver histology damage 
scoring of sham-operated rats, I/Ri rats, CORM-2 treated rats and 
iCORM-2 treated rats. *P < 0.05 vs. I/R group.
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effect on hepatocytes, at least in part, by up-regulation of
Bcl-2 and concomitant inhibition of effector caspase acti-
vation.
CORM-2 treatment inhibits production of pro-
inflammatory cytokines
Inflammatory cytokines, such as TNF-α, are released by
apoptotic and necrotic hepatocytes, vascular endothelial
cells and/or Kupffer cells and are known to play key roles
in the pathophysiology of hepatic I/Ri [34,35]. TNF-α is a
major inducer of adhesion molecules (i.e. ICAM-1) on
vascular endothelial cells and triggers the production of
neutrophil attracting CXC chemokines [36,37]. Together,
this leads to sinusoidal endothelial cell death and further
hepatocyte damage. To determine whether the cytopro-
tective effect of CORM-2 was associated with a decrease
in expression of this important pro-inflammatory media-
tor, we assessed serum levels of TNF-α. In line with litera-
ture, hepatic I/Ri strongly increased serum levels of TNF-
α compared to base-line levels in sham-operated rats (Fig.
3D, p < 0.001). This increase in serum levels of TNF-α
was significantly inhibited when rats were treated with
CORM-2 (Fig. 3D, p < 0.05). In contrast, iCORM-2 did
not affect serum levels of TNF-α after I/Ri (Fig. 3D).
Another important cytokine that is produced upon
hepatic I/Ri is IL-6, which has long been assumed to play
a pivotal role in liver tissue damage and as such is consid-
ered to be an important marker for the severity of tissue
injury [38,39]. In our rat model, hepatic I/Ri induced high
serum levels of IL-6 indicative of sever hepatic injury (Fig.
3E, p < 0.001). Of note, serum levels of IL-6 were signifi-
cantly inhibited by treatment with CORM-2 (Fig. 3E, p <
0.05). Again, iCORM-2 did not have any effect (Fig. 3E).
Thus, the induction of pro-inflammatory cytokines dur-
Figure 2 CORM-2 treatment inhibits apoptosis in hepatic I/Ri. He-
patocyte apoptosis was visualised by TUNEL staining in biopsies of A 
Sham-operated rats, B I/Ri-treated rats, C CORM-2 treated rats, D 
iCORM-2 treated rats. E. Graph of the apoptotic index in the various 
treatment groups. *P < 0.05 vs. I/R group.
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ing hepatic I/Ri is markedly decreased by treatment with
CORM-2.
CORM-2 treatment prevents ICAM-1 expression and 
decreases neutrophil infiltration
To further clarify the mechanism of the protective effect
of CORM-2 treatment, we assessed whether CORM-2
treatment also had an effect on neutrophil infiltration
and activation. An important step in the tissue infiltration
o f  l e u k o cy t e s  i s  t h e  e x p r e s s i o n  o f  a d h e s i o n  m o l e c u l e s,
such as ICAM-1, on vascular endothelial cells [40,41].
Indeed, down-regulation of ICAM-1 on vascular
endothelial cells can attenuate hepatic I/Ri both in vitro
and  in vivo [42,43]. Several studies have shown that
ICAM-1 is essential for leukocyte attachment and infil-
tration through endothelial cell lining in hepatic sinu-
soids [44,45]. Our data confirmed that expression of
ICAM-1 in the liver was up-regulated as a result of
hepatic I/Ri (Fig. 3A and 3B, p < 0.001). Moreover,
administration of CORM-2, but not iCORM-2, markedly
inhibited the ICAM-1 expression as induced by I/Ri (Fig.
3A and 3B, p < 0.05).
Next, we assessed whether this reduction in ICAM-1
expression was accompanied by a reduction in neutrophil
infiltration. Neutrophil infiltration and activation is an
important measure for tissue inflammation and can be
quantified by determining tissue myeloperoxidase (MPO)
activity [46]. MPO activity in the liver obtained from the
I/Ri group was markedly increased compared with livers
obtained from sham operated rats (Fig. 3F, p < 0.001).
Consistent with the improvement in liver function, the
activity of MPO significantly decreased upon CORM-2
administration (Fig. 3F, p < 0.05). In contrast, treatment
with iCORM-2 did not affect tissue MPO activity. Thus,
the expression of adhesion molecules and the subsequent
tissue infiltration of leukocytes, in particular neutrophils,
after hepatic I/Ri was effectively reduced by CORM-2
treatment.
CORM-2 blocks pro-inflammatory NF-κB signaling in vivo
The coordinated induction of hepatocyte apoptosis, the
expression of pro-inflammatory cytokines, and the
expression of vascular endothelial cell adhesion mole-
cules results in the adhesion and migration of neutrophils
and ultimately liver injury. All of these factors are known
to be at least partly regulated by the transcription factor
NF-κB. The active NF-κB unit involved in the pro-inflam-
matory response is the p50/p65 heterodimer, of which
the p65 subunit provides the gene regulatory function. In
order to evaluate whether the observed beneficial effects
of CORM-2 was associated with a down-modulation of
NF-κB activity, we assessed p65 subunit NF-κB DNA
binding activity in hepatic nuclear extracts. I/Ri induced a
significant increase in NF-κB p65 DNA binding activity
(Fig. 4A, p < 0.001). This increase in I/Ri rats was signifi-
cantly inhibited in hepatic nuclear extracts of I/Ri rats
treated with CORM-2 (Fig. 4A, p < 0.05). In contrast,
iCORM-2 had no effect on the activation of NF-κB. This
effect of CORM-2 treatment on NF-κB was further con-
firmed by western blot detection of the presence of the
p65 subunit in the nuclear fraction, which revealed a clear
increase in protein levels of p65 subunit NF-κB in
untreated I/R rats and iCORM-2 treated I/R rats (Fig.
4B). However, this translocation was inhibited by treat-
ment with CORM-2 (Fig. 4B). Subsequent quantitation
by densitometry revealed that CORM-2 treatment
induced a significant reduction in nuclear translocation
of the p65 subunit of NF-κB compared to untreated I/R
rats and iCORM-2 treated I/R rats (Fig. 4C, p < 0.05).
Taken together, these data indicate that the hepatoprotec-
tive effect of CORM-2 was in part due to down-regula-
tion of the inflammatory mediators and inhibition of NF-
κB activation.
I/Ri-induced HO-1 expression is further augmented by 
CORM-2 treatment
The induction of HO-1 is an important cellular stress
response that is induced by ischemia reperfusion. There-
fore, we next assessed whether HO-1 expression was up-
regulated by I/Ri and whether CORM-2 treatment had
modulatory effects on this stress response. As antici-
pated, HO-1 expression in the liver obtained from I/Ri
group was markedly increased compared to sham-oper-
ated animals. Interestingly, CORM-2 but not iCORM-2
Figure 4 CORM-2 blocks pro-inflammatory NF-κB signalling in vi-
vo. NF-κB activation was determined using A ELISA-based TransAM 
NF-κB p65 kit and B visualised using western blot followed by C densi-
tometry analysis.*P < 0.05 vs. I/R group.
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treatment induced a further significant up-regulation of
HO-1 (Fig. 3A and 3C, p < 0.05). These data confirm ear-
lier studies, in which activation of the HO system by an
HO-1 inducer or by HO-1 gene therapy displayed
enhancement of hepatoprotection against warm and cold
I/Ri in experimental animals [47,48]. Thus, CORM-2
treatment, by inducing local CO-production can help to
increase HO-1 expression and thereby further augment
the cytoprotective response upon I/Ri.
Discussion
Endogenous CO produced by HO-1 is an important cel-
lular protective measure to prevent cytotoxic and pro-
inflammatory effects during reperfusion injury. Here we
show that exogenous CO released by CO-releasing mole-
cule 2 (CORM-2) can be applied to reduce hepatic isch-
emia reperfusion injury (I/Ri), a common adverse event
during liver surgery that is characterized by hepatocellu-
lar death and inflammatory cell influx. In our model we
demonstrated that CORM-2 treatment reduced the
extent of apoptosis and ameliorated the pro-inflamma-
tory stress response as evidenced by a reduction in the
expression of pro-inflammatory cytokines, vascular
endothelial adhesion molecule and a markedly reduced
influx of leukocytes
Importantly, therapeutic application of CO inhalation
is severely hampered by the deleterious effects on the
respiratory system due to carboxyhemoglobin formation.
For instance, inhalation of 500 ppm gaseous CO in
humans resulted in a peak carboxyhemoglobin level of
7%, whereas in animal studies levels of up to 25% were
detected. In contrast, treatment with CO-releasing mole-
cules such as CORM-2 does not lead to a dramatic
increase in carboxyhemoglobin. Indeed, treatment with
CORM-2 at doses up to 20 μmol/kg (10,25 mg/kg) had no
negative impact on oxy-haemoglobin saturation [48].
Thus, CORM-2 appears to be a potent inhibitor of nega-
tive effects of hepatic I/Ri, while at the same time having
no appreciable negative effects on the respiratory system.
Both the cytoprotective and anti-inflammatory activity
of CO appear to result, at least in part, from its ability to
modulate the transcription factor NF-κB. For instance,
CO-treatment of hepatocytes induces activation of NF-
κB  in vitro and in vivo [33], which renders these cells
more resistant to apoptosis by up-regulating the anti-
apoptotic protein Bcl-xL and down-regulating the pro-
apoptotic protein Bax [49]. Similarly, we found a marked
up-regulation of the anti-apoptotic protein Bcl-2 upon
CORM-2 treatment. Since the balance between pro- and
anti-apoptotic members of the Bcl-2 family is central to
the control of the mitochondrial pathway of apoptosis,
this increase in Bcl-2 expression is likely to inhibit execu-
tion of mitochondrial apoptosis. Of note, pre-treatment
of LPS-stimulated human umbilical vein endothelial cells
(HUVEC) with CO showed a reverse effect, namely inhi-
bition of NF-κB activity [50]. As a result, CO-treated
endothelial cells showed a reduced expression of adhe-
sion molecules, which may reduce pro-inflammatory
processes such as leukocyte adhesion and tissue infiltra-
tion of inflammatory cells. Thus, CO can have opposite
effects on NF-κB signaling depending on the particular
cell type involved. Further detailed investigation, using
e.g. laser dissection microscopy may yield insight into the
effect of CO on hepatocytes and hepatic vascular
endothelium in vivo. However, from the above it is clear
that these diverse effects on NF-κB cooperate to amelio-
rate cell damage and minimize inflammation.
In addition to NF-kB, protective effects of CO-released
from CORM-2 may be related to the down-regulation of
the iNOS/NO pathway in e.g. macrophages. In vitro
treatment of LPS-stimulated macrophages with CO
indeed prevented expression of iNOS and blocked the
pro-adhesive phenotype [24,51]. Furthermore, treatment
of I/Ri in a rat liver transplantation model using gaseous
CO was partly attributable to down-regulation of iNOS/
NO [16].
As anticipated, the induction of pro-inflammatory
cytokines such as TNF-α during hepatic I/Ri is markedly
decreased by treatment with CORM-2. Together with the
accompanying decrease in expression of adhesion mole-
cules these effects are likely accountable for the reduction
in influx of inflammatory cells. The exact mechanism for
down-regulation of TNF-α by CORM-2 treatment is still
a matter of debate. Various reports have indicated that
this effect might be attributable to direct CO-effects on
vascular endothelium and circulating leukocytes. Indeed,
CO has potent anti-inflammatory effects on LPS-stimu-
lated HUVEC cells and macrophages [24,25,51]. Another
possible contributing factor to the reduction in TNF-α
level upon CORM-2 treatment is the rescue of hepato-
cytes from apoptosis. Apoptosis of hepatocytes is a uni-
versal feature of liver inflammation and is associated with
the production of various inflammatory cytokines. Thus,
the marked reduction in apoptotic hepatocytes upon
CORM-2 treatment might contribute to the downplaying
of the inflammatory response.
Of note, exogenous application of CORM-2 had an aug-
menting effect on the expression levels of HO-1, indicat-
ing that the exogenous addition of one of the reaction
products of HO-1 has a positive feed forward effect on
HO-1 expression. Since activation of the HO system by
an HO-1 inducer or by HO-1 gene therapy enhances
hepatoprotection against warm and cold I/Ri in experi-
mental animals [46,47], HO-1 upregulation upon treat-
ment with CORM-2 may contribute to the beneficial
effects on severity of I/Ri. Indeed, products of the HO-1
enzyme such as bilirubin have well-documented cytopro-
tective and anti-oxidative activity. Further experiments,Wei et al. BMC Gastroenterology 2010, 10:42
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e.g. using specific HO-1 inhibitors such as zink protopo-
rhyrin or OB-14 [52], may be used in conjunction with
CORM-2 treatment to determine the relative contribu-
tion of these HO-1 products."
Conclusion
In conclusion, exogenous CO as released by CORM-2
treatment has a cytoprotective effect during hepatic I/Ri,
most likely mediated by the initial attenuation of apopto-
sis induction, followed by reduced expression of inflam-
matory mediators and adhesion molecules, and a
concomitant decrease in neutrophil infiltration. Together
with recent experimental evidence of beneficial effects of
CORMs in kidney and small bowel I/Ri [26,53], these
data clearly highlight the potential of CO-releasing mole-
cules such as CORM-2 for the prevention or amelioration
of I/Ri damage. Therefore, further pre-clinical investiga-
tion into the therapeutic applicability of controlled CO-
release by CORM-2 for the prevention of I/Ri in hepatic
surgery is warranted.
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